Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

15 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Residual cancer burden after neoadjuvant chemotherapy and long-term survival outcomes in breast cancer: a multicentre pooled analysis of 5161 patients.
Yau C, Osdoit M, van der Noordaa M, Shad S, Wei J, de Croze D, Hamy AS, Laé M, Reyal F, Sonke GS, Steenbruggen TG, van Seijen M, Wesseling J, Martín M, Del Monte-Millán M, López-Tarruella S; I-SPY 2 Trial Consortium; Boughey JC, Goetz MP, Hoskin T, Gould R, Valero V, Edge SB, Abraham JE, Bartlett JMS, Caldas C, Dunn J, Earl H, Hayward L, Hiller L, Provenzano E, Sammut SJ, Thomas JS, Cameron D, Graham A, Hall P, Mackintosh L, Fan F, Godwin AK, Schwensen K, Sharma P, DeMichele AM, Cole K, Pusztai L, Kim MO, van 't Veer LJ, Esserman LJ, Symmans WF. Yau C, et al. Among authors: van der noordaa m. Lancet Oncol. 2022 Jan;23(1):149-160. doi: 10.1016/S1470-2045(21)00589-1. Epub 2021 Dec 11. Lancet Oncol. 2022. PMID: 34902335 Free PMC article.
Predicted sensitivity to endocrine therapy for stage II-III hormone receptor-positive and HER2-negative (HR+/HER2-) breast cancer before chemo-endocrine therapy.
Du L, Yau C, Brown-Swigart L, Gould R, Krings G, Hirst GL, Bedrosian I, Layman RM, Carter JM, Klein M, Venters S, Shad S, van der Noordaa M, Chien AJ, Haddad T, Isaacs C, Pusztai L, Albain K, Nanda R, Tripathy D, Liu MC, Boughey J, Schwab R, Hylton N, DeMichele A, Perlmutter J, Yee D, Berry D, Van't Veer L, Valero V, Esserman LJ, Symmans WF. Du L, et al. Among authors: van der noordaa m. Ann Oncol. 2021 May;32(5):642-651. doi: 10.1016/j.annonc.2021.02.011. Epub 2021 Feb 19. Ann Oncol. 2021. PMID: 33617937 Free article. Clinical Trial.
Pathologic response of ductal carcinoma in situ to neoadjuvant systemic treatment in HER2-positive breast cancer.
Groen EJ, van der Noordaa MEM, Schaapveld M, Sonke GS, Mann RM, van Ramshorst MS, Lips EH, Vrancken Peeters MTFD, van Duijnhoven FH, Wesseling J. Groen EJ, et al. Among authors: van der noordaa mem. Breast Cancer Res Treat. 2021 Aug;189(1):213-224. doi: 10.1007/s10549-021-06235-2. Epub 2021 May 4. Breast Cancer Res Treat. 2021. PMID: 33945043 Free PMC article.
Minimally Invasive Complete Response Assessment of the Breast After Neoadjuvant Systemic Therapy for Early Breast Cancer (MICRA trial): Interim Analysis of a Multicenter Observational Cohort Study.
van Loevezijn AA, van der Noordaa MEM, van Werkhoven ED, Loo CE, Winter-Warnars GAO, Wiersma T, van de Vijver KK, Groen EJ, Blanken-Peeters CFJM, Zonneveld BJGL, Sonke GS, van Duijnhoven FH, Vrancken Peeters MTFD. van Loevezijn AA, et al. Among authors: van der noordaa mem. Ann Surg Oncol. 2021 Jun;28(6):3243-3253. doi: 10.1245/s10434-020-09273-0. Epub 2020 Dec 2. Ann Surg Oncol. 2021. PMID: 33263830 Free PMC article.
Breast-Conserving Therapy in Patients with cT3 Breast Cancer with Good Response to Neoadjuvant Systemic Therapy Results in Excellent Local Control: A Comprehensive Cancer Center Experience.
van der Noordaa MEM, Ioan I, Rutgers EJ, van Werkhoven E, Loo CE, Voorthuis R, Wesseling J, van Urk J, Wiersma T, Dezentje V, Vrancken Peeters MTFD, van Duijnhoven FH. van der Noordaa MEM, et al. Ann Surg Oncol. 2021 Nov;28(12):7383-7394. doi: 10.1245/s10434-021-09865-4. Epub 2021 May 12. Ann Surg Oncol. 2021. PMID: 33978889
Three-year follow-up of de-escalated axillary treatment after neoadjuvant systemic therapy in clinically node-positive breast cancer: the MARI-protocol.
van Loevezijn AA, van der Noordaa MEM, Stokkel MPM, van Werkhoven ED, Groen EJ, Loo CE, Elkhuizen PHM, Sonke GS, Russell NS, van Duijnhoven FH, Vrancken Peeters MTFD. van Loevezijn AA, et al. Among authors: van der noordaa mem. Breast Cancer Res Treat. 2022 May;193(1):37-48. doi: 10.1007/s10549-022-06545-z. Epub 2022 Mar 3. Breast Cancer Res Treat. 2022. PMID: 35239072 Free PMC article.
Identifying pathologic complete response of the breast after neoadjuvant systemic therapy with ultrasound guided biopsy to eventually omit surgery: Study design and feasibility of the MICRA trial (Minimally Invasive Complete Response Assessment).
van der Noordaa MEM, van Duijnhoven FH, Loo CE, van Werkhoven E, van de Vijver KK, Wiersma T, Winter-Warnars HAO, Sonke GS, Vrancken Peeters MTFD. van der Noordaa MEM, et al. Breast. 2018 Aug;40:76-81. doi: 10.1016/j.breast.2018.04.015. Epub 2018 May 22. Breast. 2018. PMID: 29698928
[No title available]
[No authors listed] [No authors listed] PMID: 33031572
Major Reduction in Axillary Lymph Node Dissections After Neoadjuvant Systemic Therapy for Node-Positive Breast Cancer by combining PET/CT and the MARI Procedure.
van der Noordaa MEM, van Duijnhoven FH, Straver ME, Groen EJ, Stokkel M, Loo CE, Elkhuizen PHM, Russell NS, Vrancken Peeters MTFD. van der Noordaa MEM, et al. Among authors: van duijnhoven fh. Ann Surg Oncol. 2018 Jun;25(6):1512-1520. doi: 10.1245/s10434-018-6404-y. Epub 2018 Mar 6. Ann Surg Oncol. 2018. PMID: 29511992
15 results